Clinical Trials in San Dimas, California
17 recruiting
Showing 1–16 of 16 trials
Recruiting
Phase 3
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
Heart Failure
Boehringer Ingelheim6,000 enrolled652 locationsNCT06424288
Recruiting
Phase 2
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease
Chronic Kidney Disease
Boehringer Ingelheim416 enrolled153 locationsNCT06926660
Recruiting
Phase 2
Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease
Diabetic Kidney Disease (DKD)
Regeneron Pharmaceuticals270 enrolled29 locationsNCT07271186
Recruiting
Phase 2
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
Chronic Kidney Disease
Novo Nordisk A/S465 enrolled147 locationsNCT06717698
Recruiting
Phase 3
A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation
Heart Failure
Novo Nordisk A/S5,600 enrolled1117 locationsNCT05636176
Recruiting
Phase 1Phase 2
A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)
Staphylococcus Aureus
AstraZeneca231 enrolled41 locationsNCT06749457
Recruiting
Phase 3
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
COPD, Chronic Obstructive Pulmonary Disease
AstraZeneca5,000 enrolled917 locationsNCT06283966
Recruiting
Phase 2Phase 3
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis
End-stage Kidney DiseaseAtherosclerotic Cardiovascular DiseaseAtherosclerotic Cardiovascular Disease in Patients With ESKD
CSL Behring2,310 enrolled468 locationsNCT05485961
Recruiting
Phase 3
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
Primary IgA Nephropathy
Novartis Pharmaceuticals540 enrolled161 locationsNCT04557462
Recruiting
Phase 3
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
HypertensionHigh Risk Cardiovascular DiseaseHigh Cardiovascular Risk
Alnylam Pharmaceuticals11,000 enrolled229 locationsNCT07181109
Recruiting
Phase 3
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
Heart Failure
AstraZeneca11,300 enrolled917 locationsNCT06677060
Recruiting
Phase 3
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
Atrial Fibrillation (AF)
Anthos Therapeutics, Inc.1,900 enrolled721 locationsNCT05712200
Recruiting
Phase 2
A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis
Rheumatoid Arthritis
AstraZeneca320 enrolled124 locationsNCT07276581
Recruiting
Phase 3
A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China
HyperphosphatemiaDialysisChronic Kidney Disease, Receiving Dialysis+1 more
Alebund Pharmaceuticals264 enrolled42 locationsNCT06933472
Recruiting
Phase 3
Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
Chronic Kidney DiseasesType 2 Diabetes Mellitus
Prokidney685 enrolled86 locationsNCT05099770
Recruiting
Not Applicable
Moda-flx Hemodialysis System™ Under Professional Care Settings by Trained Individuals and At Home by Participants
End-stage Kidney Disease
Diality Inc.50 enrolled4 locationsNCT06613568